BBIO

Bridgebio Pharma Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 3/10
  • Value↓ 0/10
Bridgebio Pharma sales and earnings growth
BBIO Growth
Neutral
  • Revenue Y/Y↑ 126.26%
  • EPS Y/Y↓ -31.25%
  • FCF Y/Y↑ 14.31%
Bridgebio Pharma gross and profit margin trends
BBIO Profitability
Good
  • Gross margin ↑ 95.80%
  • EPS margin↓ -144.40%
  • ROIC 5Y↓ -26.84%
Bridgebio Pharma net debt vs free cash flow
BBIO Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 2.9
  • Interest coverage↓ -12.6

Bridgebio Pharma stock volatility is in-line with the overall market. We give it a Poor risk rating.

More Biotechnology stocks ↗